On April 14, 2023 Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, reported that the company will present four poster presentations at the 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place in Orlando, FL on April 14-19, 2023 (Press release, Bicycle Therapeutics, APR 14, 2023, View Source [SID1234630081]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Details:

Title: Modulation of natural killer cell immune response to tumor with novel synthetic tumor-immune cell agonist, NK-TICA
Session Title: Immunomodulatory Agents and Interventions 1
Date and Time: Monday, April 17, 2023 at 9:00 a.m. ET
Abstract Number: 1806
Speaker/Lead Author: Fay Dufort, Bicycle Therapeutics

Title: Development of in vivo models for evaluation of NK-TICA, novel Bicycle tumor-targeted immune cell agonist designed to engage NK cells
Session Title: Immunomodulatory Agents and Interventions 1
Date and Time: Monday, April 17, 2023 at 9:00 a.m. ET
Abstract Number: 1826
Speaker/Lead Author: Lukas Stanczuk, Bicycle Therapeutics

Title: EphA2-dependent CD137 agonism and anti-tumor efficacy by BT7455, a Bicycle tumor-targeted immune cell agonist
Session Title: Immunomodulatory Agents and Interventions 2
Date and Time: Monday, April 17, 2023 at 9:00 a.m. ET
Abstract Number: 1832
Speaker/Lead Author: Lia Luus, Bicycle Therapeutics

Title: Phase 1/2 study of the safety, pharmacokinetics, and preliminary clinical activity of BT7480 in patients with Nectin-4 associated advanced malignancies
Session Title: Phase I and First-in-Human Clinical Trials in Progress
Date and Time: Tuesday, April 18, 2023 at 1:30 p.m. ET
Abstract Number: CT253
Speaker/Lead Author: Thomas R. Jeffry Evans, MBBS: School of Cancer Sciences, University of Glasgow

The posters will be made available on the Publications section of bicycletherapeutics.com following the presentations.

On April 14, 2023 Bexion Pharmaceuticals, Inc., a mid-stage clinical biopharmaceutical company developing a new generation of biologic immunotherapy to treat solid tumor cancers and Chemotherapy Induced Peripheral Neuropathy (CIPN), reported that the Company will be represented at two upcoming prestigious scientific conferences (Press release, Bexion, APR 14, 2023, View Source [SID1234630080]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

American Association for Cancer Research Annual Meeting (AACR) (Free AACR Whitepaper) April 14-19, 2023
Orlando, Florida
Bexion is presenting two posters:

Poster 3042 1:30 pm on 4/17/2023 Section 28 Number 14
BXQ-350 May Protect from the Direct Toxicity of Chemotherapeutic Agent leading to Chemotherapy Induced Peripheral Neuropathy

Poster 4437 9:00 am on 4/18/2023 Section 40 Board Number 23
BXQ-350: A Novel Biologic with an Innovative Mechanism of Action Targeting Sphingolipid Metabolism that Induces Cancer Cell Death and Repolarizes the Tumor Environment

12th International Ceramide Conference (ICC) April 16-20, 2023
Charleston, South Carolina
Bexion has been chosen for an oral presentation and two poster sessions. Oral presentation:

Tuesday, April 18 9:10 – 9:30 am Dr. Gilles Tapolsky, Bexion Pharmaceuticals
BXQ-350: Targeting Sphingolipids and Anticancer Activity in Cancer Patients Poster presentations: Posted during meeting

BXQ-350: Modulating Ceramide and Sphingosine-1-Phospate for Anti-Tumor Activity in Cancer Patients with Advanced Disease

BXQ-350: A Novel Biologic that Modulates Sphingolipid Metabolism and Demonstrates Anti-Cancer, Anti-CIPN, and Anti-Viral Properties

On April 14, 2023 Alentis Therapeutics, the Claudin-1 company, reported that Alberto Toso, Alentis’ SVP Head of Oncology, will present at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Conference in Orlando, Florida on April 18th (Press release, Alentis Therapeutics, APR 14, 2023, View Source [SID1234630079]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster session entitled, CLAUDIN-1 targeting antibody ALE.C04 drives single agent activity and restores anti-PD1 efficacy in solid tumors, presents evidence that ALE.C04 is a highly specific humanized monoclonal antibody that recognizes a unique CLDN1-exposed epitope in different solid tumors.

Non-Junctional Claudin-1 (NJ-CLDN1) is frequently overexpressed in solid tumors. In in vivo tumor models, ALE.C04 monotherapy drives tumor growth inhibition mainly via antibody-dependent cellular cytotoxicity in different cell line-derived and patient-derived xenografts.

Notably, CLDN1 expression on tumor cells positively correlates with T-cell exclusion, a mechanism described to hinder the efficacy of checkpoint inhibitors. In mouse tumor cells, the overexpression of CLDN1 promoted T-cell exclusion and resistance to anti-PD1 treatment. Alentis has been able to demonstrate that ALE.C04 restored both T-cell infiltration and anti-PD1 efficacy in tumors. Mechanistically, CLDN1 interacts with different components involved in extracellular matrix remodeling establishing a physical barrier that excludes immune cells from the tumor nest. ALE.C04 disturbs the interface between CLDN1+ tumor cells and the stroma restoring immune cell infiltration. Our pre-clinical data showed that CLDN1 is a novel and druggable target in solid tumors and is a selective anti-CLDN1 antibody capable of driving anti-tumor activity as both single agent and in combination with anti-PD1.

ALE.C04, Alentis’ lead oncology asset, is the first treatment to target CLDN1+ tumors. Based on the pre-clinical data, Alentis is planning a first-in-human clinical trial with ALE.C04 in the second half of 2023.

Poster presentation details:

Poster Title: CLAUDIN-1 targeting antibody ALE.C04 drives single activity and restores anti-PD1 efficacy in solid tumors (Abstract #LB284)

Presenter: Alberto Toso, SVP Head of Oncology, Alentis Therapeutics

Authors: Alberto Toso, Geoffrey Teixeira, Tina Zimmermann, Stefanie Gill, Daniela Schmitter, Markus Meyer, Marion Muller, Laurent Mailly, Thomas Baumert, Luigi Manenti, Roberto Iacone. Alentis Therapeutics AG, Allschwil, Switzerland, UMR_S1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France, Strasbourg, France

Date: 18 April 2023
Time: 1:30 – 5:00 EDT
Location: Section 36

On April 14, 2023 Aclaris therapeutics presented its corporate overview (Presentation, Aclaris Therapeutics, APR 14, 2023, View Source [SID1234630075]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On April 14, 2023 Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, reported that further preclinical data supporting the company’s Radio DARPin Therapy Platform will be shared at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting held April 14-19 in Orlando, Florida (Press release, Molecular Partners, APR 14, 2023, View Source [SID1234630053]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster: "DARPins as powerful targeting agents for radioligand therapeutics"
Number: 5037
Timing: April 18, 2023, 1:30pm – 5:00pm
Presenter: Daniel Steiner, Ph.D., Senior Vice President of Research

Molecular Partners’ proprietary Radio DARPin Therapy (RDT) platform represents a unique and innovative delivery system designed to deliver radioactive payloads to solid tumors without accumulating in other tissues. Historically, small protein-based delivery vectors have accumulated in the kidney, presenting a tolerability risk.

Data within the presentation demonstrate that both the affinity and small size of DARPins can have an impact on tumor penetration. In addition to this, the data highlights that surface engineering of the DARPin backbone is a promising strategy to strongly reduce the kidney accumulation of DARPins, without affecting tumor uptake. The data also show that the addition of other orthogonal strategies results in a further reduction of kidney accumulation.

"We continue to deepen the data set supporting the distinctive target product profile of RDTs, addressing historic challenges for protein-based radionuclide vectors through the particular attributes of DARPins as an engineered protein drug class," said Daniel Steiner, Ph.D., Senior Vice President of Research at Molecular Partners. "By improving on both the potential efficacy and safety of radiotherapy, we see a true potential for the RDT platform to expand the treatable universe, beyond the traditional ligand targets and into a broad range of tumor targets."

Molecular Partners is developing candidates both in-house as well as in collaboration with Novartis, a global leader in radioligand therapies. Molecular Partners’ first disclosed target for its in-house RDT programs is Delta-like ligand 3 (DLL3), a protein which has low expression in healthy tissues but significantly increased expression in certain tumor types.

Previously reported data supporting the RDT platform presented at TAT-12 can be found here, while the latest results will be shared via a poster at AACR (Free AACR Whitepaper) 2023 on April 18. The poster will be made available on the Molecular Partners website.